Successful adjuvant trials for RET, ALK, and EGFR-positive lung cancer—mutations common in non-smokers—reveal a critical public health gap. Current USPSTF screening guidelines target smokers, meaning these early-stage, treatable cancers in non-smokers are often found by luck, not by systematic screening protocols.
The success of the Libretaro 432 trial for the rare (1%) RET fusion mutation disproves the long-held assumption that such studies are impractical. When a targeted therapy demonstrates a massive benefit, indicated by a very low hazard ratio, large thousand-patient trials become unnecessary to prove a practice-changing effect.
Bispecific antibodies, which target two antigens like PD-1 and VEGF simultaneously, are viewed as the next major upgrade to standard immunotherapy. Their 'cooperative binding' mechanism is expected to improve efficacy and safety, and early trial data suggest they could replace decade-old checkpoint inhibitors like pembrolizumab as the new standard of care.
The primary challenge in combining KRAS inhibitors with immunotherapy is managing toxicity. A severe side effect could force discontinuation of both drugs, thereby sacrificing the potential for a long-term cure from immunotherapy alone. The goal is to avoid trading overall survival for a higher initial response rate.
In neoadjuvant trials, patients who fail to achieve a pathologic complete response are scientifically invaluable. Their resected tumors, which survived initial treatment, provide critical tissue to study resistance mechanisms. This allows researchers to inform the development of better combination therapies for all stages of disease.
For cancers with mutations like BRAF or MET, where both immunotherapy and targeted therapy are viable options, smoking history can guide treatment sequencing. A heavy smoking history suggests immunotherapy may be more effective upfront, whereas targeted therapy might be preferred first for non-smokers due to differences in tumor immunogenicity.